Table 2 The proportion of HPV E6/E7 mRNA test result and its diagnostic performance of against histology, 2011–18
Author (S) | Prevalence of CIN2+, n (%) | HPV DNA test | HPV E6/E7 mRNA test | mRNA test positivity rate, n(%) | Performance of E6/E7 mRNA test | ||||
|---|---|---|---|---|---|---|---|---|---|
Sen% | Spe% | PPV% | NPV% | AU-ROC% | |||||
Ratnam, 2011 | 28.30% | Hybrid Capture 2 (HC2) | Aptima | 964 (68%) | 96.3 | 46.2 | 40.0 | 96.7 | Â |
Waldstrom, 2011 | 67(16.5) | none | Aptima | 271 (67%) | 92.5 | 38.2 | 22.9 | 96.3 | Â |
Fan, 2018 | 97 (50.5) | HC2 | Fluorescence in situ hybridization (FISH) | no data | 91.5 | 81.6 | 82.7 | 90.9 | 90.9 |
Han,2018 | 101 (51.3) | No data | No data | No data | 85.2 | 66.7 | 72.9 | 81 | 74.95 |
Binnicker,2014 | 81(23.1) | HC2 | APTIMA | 230 (65.7%) | 91.4 | 42 | 32.1 | 94.2 | Â |
Broccolo,2013 | 79 (25.6) | Quantitative real-time PCR | PreTect HPV-Proofer | 115 (37.3) | 77 | 81.7 | 66.9 | 88 | Â |
Waldstrom, 2012 | 48 (55.8) | Linear Array | Aptima | 103 (31.7%) | 87.5 | 78 | 40.8 | 97.3 | Â |
Li,2017 | 85 (26.7) | HC2 | QuantiVirus HPV E6/E7 RNA 3.0; | 177 (70.2) | 88.2 | 36.4 | 33.9 | 89.3 | 68.5 |
Benevolo,2011 | 49 (10.6) | HC2 | Pretect HPV-Proofer | 165 (36%) | 72 | 73 | 39 | 92 | Â |
Wang, 2019 | 104 (47.3) | HPV DNA chip test | Optimygene HR-HPV RT-qDx assay, | 219 (38.9) | 85.9 | 82.5 | 78.2 | 87.4 | Â |
Liu, 2014 | 57 (61.9) | No | Quantivirus® | 135 (40.3) | 71.9 | 74.3 | 82 | 61.9 | 78 |
Iftner, 2015 | 90 (14.9) | HC2 | Aptima | 464 (4.9%) | 87.8 | 96.1 | 21.1 | 99.8 | Â |
Sorbye, 2011 | 124 (23.8) | No | PreTect HPV-Proofer | 52 (27.1) | 89.1 | 92.5 | 77.3 | 96.4 | Â |
Duvlis, 2015 | 29 (47.5) | No | NucliSENS-EasyQ® (PreTect Proofer) | 74 (17.9) | 93.1 | 50 | 62 | 88.9 |  |
Castro, 2013 | 72 (43.6) | Nested PCR | NucliSENS-EasyQ® (PreTect Proofer) | 96 (58.2) | 84.1 | 80 | 90.9 | 88.9 |  |
Pierry, 2012 | 45 (18.3) | none | (HPV OncoTect | Â | 89 | 92 | 71 | Â | Â |
Alaghehbandan, 2013 | 380 (27.9) | HC2 | PreTect HPV-Proofer | 525 (38.6) | 76.1 | 68.7 | 55 | 89.1 | Â |
Clad, 2011 | 252 (59.4) | HC2 | Aptima | 274 (65) | 91.7 | 75 | Â | Â | Â |
Varnai, 2018 | 27 (81.8) | PCR-based typing | PreTect HPV-Proofer | 38 (58) | 95 | 55 | 81 | 86 | Â |
Coquillard, 2011 | 73 (28.1) | HC2 | Quantivirus® | No data | 84 | 85 | 78 | – |  |
Shen, 2013 | 31 (27.9) | HC2 | Quantivirus® | 200 (73.5) | 82.4 | 15.5 | 22.2 | 75 | 63.8 |
Li, 2016 | 103 (55.4) | HC2 | Quantivirus® | 138 (74.2) | 91.3 | 47 | 68.1 | 81.3 | 75.9 |
Liu, 2017 | 153 (40.3) | none | Quantivirus® | 275 (72.4) | 93.4 | 62.1 | 40.5 | 97.3 |  |
Benevolo, 2011 | 230 (39.2) | HC2 | PreTect HPV-Proofer | 166 (10.3) | 83 | 45 | 80 | 91 | Â |
Liu, 2018 | 155 (90.6) | SepaGene kit | RT-PCR assay | 95 (55.6) | 55 | 50 | 91 | 77 | Â |
Persson, 2014 | 73 (36.9) | Linear Array Genotyping | APTIMA | 162 (74) | 78.1 | 25 | 36.5 | 67.4 | Â |
Sorbye, 2011 | 69 (23.2) | None | PreTect HPV-Proofer | 97 (32.7) | 94.2 | 86 | 67 | 98 | Â |
Andersson, 2011 | 87 (56.1) | None | Real-time PCR | No data | 91 | 68 | 67 | 91 | Â |
Andersson, 2011 | 87 (56.1) | None | PreTect HPV-Proofer | No data | 75 | 77 | 70 | 81 | Â |
Oliveira, 2013 | 295 (53.8) | HC2 | NucliSENS EasyQ® (PreTect Proofer) | 305 (55.1) | 79.3 | 72.6 | 76.7 | 75.5 |  |